Form 4: PepGen Inc. Chief Medical Officer Michelle Mellion Reports Stock Sales Under 10b5-1 Plan

Michelle Mellion, Chief Medical Officer of PepGen Inc., reports the sale of common stock and exercise of stock options under a pre-arranged 10b5-1 trading plan.

Summary

• On July 24 and 25, 2024, Michelle Mellion, the Chief Medical Officer of PepGen Inc., executed transactions involving the company's common stock.
• These transactions included the exercise of stock options and the subsequent sale of shares.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on January 19, 2024.
• On July 24, 201 shares were acquired through option exercise at a price of $10.21 and then sold at a weighted average price of $18.0051.
• On July 25, 7,571 shares were acquired through option exercise at a price of $10.21 and then sold at a weighted average price of $18.0612.
• Following these transactions, Mellion directly owns 50,000 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Comparison to Industry Standards

• Comparing Mellion's transactions to industry standards requires analyzing similar Form 4 filings from executives at comparable biotechnology companies.
• Factors to consider include the size of the transactions relative to Mellion's holdings, the timing of the transactions in relation to company announcements, and the use of 10b5-1 plans.
• Without specific data on peer companies, a direct comparison is difficult, but the disclosure itself aligns with regulatory expectations for insider trading transparency.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they involve the sale of shares by a company insider.
• However, the existence of a 10b5-1 plan suggests that these sales are pre-planned and not necessarily indicative of the insider's view of the company's future prospects.

Key Dates